Novartis.
Swiss-American multinational pharmaceutical corporation
- Reports this week
- 5
- Active events
- 5
- Connections
- 472
What's happening
Active this week
-
Sean Maenpaa, with experience at Novartis and Celgene, was appointed SVP Business Development at Clovis Oncology.Some support1 report
-
FDA endorsed broader use of a Lilly medicine, and Abogen furnished Novartis with RNA technology.Some support1 report
-
Biotech and pharmaceutical companies in Greater Boston are seeing strategic investments, talent movement, and antibody development advances.Some support1 report
-
Novartis and Pfizer provided talent to MindWalk Holdings Corp., while Shuji Sato and Joanne Lim joined the company.Some support1 report
-
Erste Group Bank reduced its earnings per share estimates for Novartis.Some support1 report
Earlier this month
-
ABB and Novartis proposed AI solutions for energy and community health in Shanghai, supported by Tan Su Shan.Some support2 reports
-
The Nuclear Regulatory Commission proposes a draft radiation guide for Pluvicto, a drug manufactured by Novartis.Some support1 report
-
Novartis and Morgan Foods are adopting Joule, an agentic AI technology, for sourcing and business operations.Some support1 report
-
Research Triangle Park spans between Raleigh and Durham, serving as a corporate hub for companies like Lenovo and Novartis.Some support2 reports
-
Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Some support4 reports
-
GSK and Novartis are identified as major pharmaceutical companies.Some support1 report
-
Sanofi removed Sjögren's from frexalimab and Novartis discontinued iscalimab in Sjögren's.Some support1 report
-
Anthropic and Novartis are collaborating on preclinical drug discovery programs, while the rivalry between AI firms drives market focus.Some support2 reports1 development inside
-
Novartis CEO joined Anthropic's board.Some support1 report
-
Telix agreed to acquire ITM Isotope Technologies Munich and is developing drugs that compete with Novartis.Some support2 reports
-
LVMH and Hermes contribute to the global luxury goods market, while Hoffmann-La Roche and Novartis compete in the global pharmaceutical sector.Some support1 report
-
The European Medicines Agency provided a positive opinion on a drug developed by Novartis.Some support1 report
-
Titan, Novartis, and CI&T entered a licensing agreement regarding central nervous system therapeutics, competing in the small-cap technology sector.Some support1 report
One to three months ago
-
Novartis acquired Regulus Therapeutics in April, while also reportedly weighing a potential deal with Avidity Biosciences.Well supported10 reports1 development inside
-
Novartis is offering potential support to the national health fund in Ghana, which provides equipment and support to the Komfo Anokye Teaching Hospital.Some support2 reports
-
Novartis is researching potential cures for Chagas disease in the Americas.Some support1 report
-
Novartis sought Swissmedic regulatory approval for a drug, which was co-funded by Sida and introduced first in Ghana.Some support1 report
-
Novartis and Novo Nordisk experienced simultaneous major drug program failures on September 14, 2026.Some support1 report
-
The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.Some support1 report
-
Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).Some support2 reports7 developments inside
-
Amgen and Novartis have developed similar drugs aimed at treating heart conditions.Some support6 reports2 developments inside
-
A rival's trial failure has challenged the shared scientific hypothesis between Amgen and Novartis.Some support1 report
-
Monte Rosa Therapeutics announced a global license agreement with Novartis and a strategic collaboration with Roche.Well supported6 reports1 development inside
-
The market is reacting to the news of Novartis' drug trial failures, specifically impacting Amgen's stock performance on the Nasdaq exchange.Some support2 reports
-
Daiichi Sankyo co-developed datopotamab deruxtecan with partners, and Jim Cramer compared AstraZeneca to Novartis.Some support2 reports
-
Avidity Biosciences, a San Diego-based company, announced a partnership with Eli Lilly and is also facing acquisition interest from Novartis.Well supported7 reports1 development inside
-
Major pharmaceutical companies, including Novartis, Roche, AstraZeneca, and Pfizer, maintain significant presences in Switzerland.Some support2 reports2 developments inside
-
Bank of America maintained its Buy rating on Novartis shares.Some support2 reports
-
Ionis Pharmaceuticals and Novartis co-developed heart drug Pelacarsen and are seeking regulatory approval for drug trials.Some support1 report
-
Dr. Iyengar gained experience during his tenure, involving companies such as Incyte, Novartis, and McKinsey & Company.Some support1 report
-
Novartis and Amgen stocks are declining, putting pressure on the Dow Jones Industrial Average due to their shared focus on cholesterol-targeting drugs.Some support1 report
-
Report covers clinical trials for Mycosis Fungoides involving Bristol-Myers Squibb, Johnson & Johnson, Merck, and Novartis.Some support3 reports1 development inside
-
Bristol-Myers Squibb paused clinical trials following clinical setbacks reported by Novartis.Some support2 reports
-
Novartis AG is subject to US federal securities laws.Some support1 report
-
Steve Rudderham held executive roles at Novartis, Syngenta, AkzoNobel, and Genpact before joining Aokah's Advisory Board.Some support1 report1 development inside
-
Amgen benefits from Novartis/Ionis Phase 3 research, Mizuho raised price targets, and the company faces a tax dispute resolution timeline.Some support4 reports
-
Iran threatens retaliation against energy infrastructure, late-stage drug trials failed, and a sweetened takeover offer was made for a former phone monopoly.Some support2 reports
-
Novartis's trial setbacks are negatively affecting market sentiment and causing a stock decline.Some support2 reports
-
Bank of America estimates the potential sales of the drug remibrutinib manufactured by Novartis.Some support4 reports
-
Novartis shares declined due to drug failure amidst geopolitical concerns regarding Iran and Oman, while Infineon benefited from an upgrade.Well supported3 reports
-
On September 7, 2026, various global events were reported, including oil price rises, tit-for-tat strikes, an election setback for Chancellor Merz, and a drug trial failure impacting a major pharmaceutical company.Some support2 reports
-
Novartis operated through a wholly owned subsidiary in India on July 1, 2026.Some support2 reports1 development inside
-
Novartis is shifting its R&D focus to India, moving operations outside of Switzerland.Some support1 report
-
Novartis' trial results are impacting Royalty Pharma's investment decisions.Some support1 report
-
Pelacarsen Phase 3 trial failure involving Ionis Pharmaceuticals and Novartis.Some support3 reports
-
Novartis announced that the Lp(a)HORIZON clinical trial failed to meet its primary endpoint on September 1, 2026.Some support3 reports
-
Anthropic has seen several high-profile appointments, including Ben Bernanke, Richard Fontaine, and a Netflix co-founder joining its trust and board.Some support1 report
-
Novartis is headquartered in Basel, Switzerland.Some support1 report1 development inside
-
Novartis is relocating activities from its Kleinbasel site and shifting production to other existing facilities across Europe.Some support2 reports
-
Novartis utilizes SAP for core inventory management.Some support1 report
-
Novartis conducted REMODEL trials for remibrutinib.Some support2 reports
-
Partnership expands Novartis's oncology pipeline.Some support2 reports2 developments inside
-
Clinical trials for a CAR-T therapy, rap-cel, have been paused due to severe adverse events.Some support1 report
-
Novartis reaches an agreement that unlocks Alteogen's technology for use in injections.Some support2 reports
-
Global biotechnology company CSL, headquartered in Melbourne, focuses on specialty biotherapies and supplies raw materials for many therapies.Some support2 reports1 development inside
No events began in the chosen period. Widen it, or reset.
What's reaching Novartis
Events traced to Novartis, step by step, newest firstAround Novartis this week
News at the entities that move Novartis most-
European Commission StructuralFrance and Germany are calling for new EU market tools to address mounting trade pressure and unsustainable deficits from China.Moves Novartis
-
European Medicines Agency TransactionalGlenn attended a congress in Amsterdam and participated in a panel with an official from the European Medicines Agency.Moves Novartis
-
Bristol-Myers Squibb OperationalBristol-Myers Squibb and Özlem Türeci presented late-stage oncology pipeline data and joint development activity in Mainz.Moves Novartis
-
Donald Trump OperationalGreg Gianforte attended a political rally hosted by Donald Trump on October 15, 2026.Moves Novartis
-
Amgen OperationalLaurus Labs is shifting focus from building to filling capacity and may participate in Amgen's supply chain.Moves Novartis
-
Monte Rosa Therapeutics StructuralTD Cowen upgraded the stock rating for Monte Rosa Therapeutics.Moves Novartis
Connections
The 40 strongest of 472, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Avidity Structural
Novartis acquired Avidity Biosciences in a $12 billion buyout and continues to integrate its technology into its drug development pipeline.
-
Regulus Structural
Novartis acquired Regulus, establishing it as a subsidiary contributing to the company's pipeline.
-
Amgen Operational
Amgen and Novartis are direct competitors in the biopharmaceutical market, where clinical trial outcomes and market events of one significantly impact the other's stock performance and risk profile.
-
Monte Rosa Therapeutics Structural
Monte Rosa Therapeutics and Novartis maintain a formal, ongoing partnership through global and exclusive licensing agreements for drug development.
-
Vas Narasimhan Structural
Vas Narasimhan serves as the CEO of Novartis, managing the company through operational challenges and strategic setbacks.
-
European Commission Structural
Novartis's ability to market its treatments in the EU depends on formal regulatory approval granted by the European Commission.
-
Fiona Marshall Structural
Fiona Marshall holds the executive position of President of Biomedical Research at Novartis.
-
Ionis Pharmaceuticals Structural
Novartis holds global rights from Ionis for the joint development and commercialization of advanced experimental drugs.
Show all 40 connections
-
onasemnogene abeparvovec Structural
Novartis is the company that develops, licenses, and brings the onasemnogene abeparvovec gene therapy product to market.
-
CSL Limited Transactional
Novartis divested its influenza vaccines business unit to CSL Limited, leading to the formation of Seqirus.
-
Pfizer Transactional
Novartis acquired Pfizer's Minipress brand and trademarks in India.
-
Arrowhead Pharmaceuticals Structural
Novartis licensed Arrowhead's ARO-SNCA therapy, gaining exclusive rights for development and commercialization.
-
Morphosys Structural
Novartis acquired Morphosys, establishing it as a subsidiary, and the two entities maintain ongoing collaboration agreements.
-
Regulus Therapeutics Structural
Novartis acquired Regulus Therapeutics, establishing it as a subsidiary to expand its biopharmaceutical portfolio.
-
Health Canada Transactional
Health Canada granted Novartis regulatory approval for the drug Vanrafia, establishing a formal dependency.
-
Eli Lilly and Company Operational
The relationship is intense market competition, rooted in the historical divestiture of Novartis' Animal Health division to Lilly.
-
FDA Structural
FDA functions as the formal regulatory body that grants, tracks, and revokes market authorizations for Novartis' pharmaceutical products.
-
Zack Structural
Zack held clinical leadership roles at Novartis.
-
Cognizant Structural
Cognizant is contracted to implement AI-enabled integrated IT operations services for Novartis.
-
European Medicines Agency Transactional
The EMA issued a positive regulatory opinion regarding a specific drug developed by Novartis.
-
Memorial Sloan Kettering Cancer Center Structural
A functional clinical trial partnership exists between Memorial Sloan Kettering Cancer Center and Novartis, based on shared expert opinion and research goals.
-
Natco Pharma Operational
The two companies are engaged in direct market competition regarding the patent exclusivity of the drug ribociclib.
-
Hoffmann-La Roche Transactional
Novartis completed the divestiture by selling its investment stake in Hoffmann-La Roche.
-
Bristol-Myers Squibb Operational
The two companies are direct, high-stakes competitors in the advanced clinical development of treatments for myeloma.
-
Fiona Marshall Structural
Fiona Marshall holds a leadership role as president of biomedical research within the organizational structure of Novartis.
-
ReGenX Biosciences (United States) Structural
ReGenX Biosciences monetizes royalties from Novartis' Zolgensma, establishing a formal licensing and operational dependency.
-
SAP Structural
Novartis utilizes SAP for core inventory management.
-
Swissmedic Structural
Novartis relies on Swissmedic for product approval and market access in Switzerland.
-
Teva Pharmaceutical Industries Ltd. Operational
Novartis and Teva actively compete in the global pharmaceutical market, particularly in generics and biosimilars.
-
Merck Operational
The companies are direct competitors in the advanced therapies market and are frequently grouped as top holdings in sector-specific ETFs.
-
Sandoz Structural
Sandoz was historically a subsidiary of Novartis following a spin-off.
-
Alnylam Pharmaceuticals Structural
Novartis and Alnylam maintain a structural partnership where Novartis is responsible for commercializing Alnylam's therapeutic products.
-
SEC Structural
Novartis is subject to regulatory oversight and required filings by the SEC.
-
Donald Trump Operational
Donald Trump's political actions, including administration policies and tariff threats, directly influence the operational environment and profitability of Novartis.
-
Genmab Transactional
Genmab receives royalty revenue from Novartis stemming from their collaboration on Kesimpta.
-
Sarepta Therapeutics Operational
The companies are active competitors in the gene therapy space while also maintaining a formal collaboration agreement.
-
Johnson & Johnson Operational
Both Johnson & Johnson and Novartis are large pharmaceutical companies that actively compete in the oncology market.
-
Arkansas Structural
The state board of Arkansas holds formal regulatory power over Novartis regarding drug distribution and market operations.
-
Titan Transactional
The companies established a licensing agreement concerning central nervous system therapeutics.
-
William Makis Structural
William Makis's contributions to therapy development are critical to Novartis's revenue generation.
History
Events by the month they beganOctober 2026
9 events- Sean Maenpaa, with experience at Novartis and Celgene, was appointed SVP Business Development at Clovis Oncology.
- FDA endorsed broader use of a Lilly medicine, and Abogen furnished Novartis with RNA technology.
- Biotech and pharmaceutical companies in Greater Boston are seeing strategic investments, talent movement, and antibody development advances.
- Novartis and Pfizer provided talent to MindWalk Holdings Corp., while Shuji Sato and Joanne Lim joined the company.
- Erste Group Bank reduced its earnings per share estimates for Novartis.
- ABB and Novartis proposed AI solutions for energy and community health in Shanghai, supported by Tan Su Shan.
- The Nuclear Regulatory Commission proposes a draft radiation guide for Pluvicto, a drug manufactured by Novartis.
- Novartis and Morgan Foods are adopting Joule, an agentic AI technology, for sourcing and business operations.
- Research Triangle Park spans between Raleigh and Durham, serving as a corporate hub for companies like Lenovo and Novartis.
September 2026
38 events- Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.
- GSK and Novartis are identified as major pharmaceutical companies.
- Sanofi removed Sjögren's from frexalimab and Novartis discontinued iscalimab in Sjögren's.
- Novartis CEO joined Anthropic's board.
- Telix agreed to acquire ITM Isotope Technologies Munich and is developing drugs that compete with Novartis.
- LVMH and Hermes contribute to the global luxury goods market, while Hoffmann-La Roche and Novartis compete in the global pharmaceutical sector.
- The European Medicines Agency provided a positive opinion on a drug developed by Novartis.
- Titan, Novartis, and CI&T entered a licensing agreement regarding central nervous system therapeutics, competing in the small-cap technology sector.
- Novartis is offering potential support to the national health fund in Ghana, which provides equipment and support to the Komfo Anokye Teaching Hospital.
- Novartis is researching potential cures for Chagas disease in the Americas.
- Novartis sought Swissmedic regulatory approval for a drug, which was co-funded by Sida and introduced first in Ghana.
- Novartis and Novo Nordisk experienced simultaneous major drug program failures on September 14, 2026.
- The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.
- Amgen and Novartis have developed similar drugs aimed at treating heart conditions.
- A rival's trial failure has challenged the shared scientific hypothesis between Amgen and Novartis.
- The market is reacting to the news of Novartis' drug trial failures, specifically impacting Amgen's stock performance on the Nasdaq exchange.
- Daiichi Sankyo co-developed datopotamab deruxtecan with partners, and Jim Cramer compared AstraZeneca to Novartis.
- Bank of America maintained its Buy rating on Novartis shares.
- Ionis Pharmaceuticals and Novartis co-developed heart drug Pelacarsen and are seeking regulatory approval for drug trials.
- Dr. Iyengar gained experience during his tenure, involving companies such as Incyte, Novartis, and McKinsey & Company.
- Novartis and Amgen stocks are declining, putting pressure on the Dow Jones Industrial Average due to their shared focus on cholesterol-targeting drugs.
- Bristol-Myers Squibb paused clinical trials following clinical setbacks reported by Novartis.
- Novartis AG is subject to US federal securities laws.
- Iran threatens retaliation against energy infrastructure, late-stage drug trials failed, and a sweetened takeover offer was made for a former phone monopoly.
- Novartis's trial setbacks are negatively affecting market sentiment and causing a stock decline.
- Bank of America estimates the potential sales of the drug remibrutinib manufactured by Novartis.
- Novartis shares declined due to drug failure amidst geopolitical concerns regarding Iran and Oman, while Infineon benefited from an upgrade.
- On September 7, 2026, various global events were reported, including oil price rises, tit-for-tat strikes, an election setback for Chancellor Merz, and a drug trial failure impacting a major pharmaceutical company.
- Novartis is shifting its R&D focus to India, moving operations outside of Switzerland.
- Novartis' trial results are impacting Royalty Pharma's investment decisions.
- Pelacarsen Phase 3 trial failure involving Ionis Pharmaceuticals and Novartis.
- Novartis announced that the Lp(a)HORIZON clinical trial failed to meet its primary endpoint on September 1, 2026.
- Anthropic has seen several high-profile appointments, including Ben Bernanke, Richard Fontaine, and a Netflix co-founder joining its trust and board.
- Novartis is relocating activities from its Kleinbasel site and shifting production to other existing facilities across Europe.
- Novartis utilizes SAP for core inventory management.
- Novartis conducted REMODEL trials for remibrutinib.
- Clinical trials for a CAR-T therapy, rap-cel, have been paused due to severe adverse events.
- Novartis reaches an agreement that unlocks Alteogen's technology for use in injections.
July 2026
3 events- Anthropic and Novartis are collaborating on preclinical drug discovery programs, while the rivalry between AI firms drives market focus.
- Amgen benefits from Novartis/Ionis Phase 3 research, Mizuho raised price targets, and the company faces a tax dispute resolution timeline.
- Novartis operated through a wholly owned subsidiary in India on July 1, 2026.
Show 1 earlier month
June 2026
10 events- Novartis acquired Regulus Therapeutics in April, while also reportedly weighing a potential deal with Avidity Biosciences.
- Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).
- Monte Rosa Therapeutics announced a global license agreement with Novartis and a strategic collaboration with Roche.
- Avidity Biosciences, a San Diego-based company, announced a partnership with Eli Lilly and is also facing acquisition interest from Novartis.
- Major pharmaceutical companies, including Novartis, Roche, AstraZeneca, and Pfizer, maintain significant presences in Switzerland.
- Report covers clinical trials for Mycosis Fungoides involving Bristol-Myers Squibb, Johnson & Johnson, Merck, and Novartis.
- Steve Rudderham held executive roles at Novartis, Syngenta, AkzoNobel, and Genpact before joining Aokah's Advisory Board.
- Novartis is headquartered in Basel, Switzerland.
- Partnership expands Novartis's oncology pipeline.
- Global biotechnology company CSL, headquartered in Melbourne, focuses on specialty biotherapies and supplies raw materials for many therapies.